Vedanta Biosciences secures $60 million to complete Phase 3 trial of microbiome therapy for C. difficile
Vedanta Biosciences has raised $60 million from investors to fund the completion of a Phase 3 study for its microbiome-based treatment targeting C. difficile infection. The Cambridge, MA-based biotech aims to read out results next year. This investment underscores continued interest in microbiome therapies for infectious diseases.
Related stories
NeuShen secures $80M to advance three clinical-stage brain therapies · Drug development
Novartis' remibrutinib shows positive Phase 3 results in relapsing MS · Drug development
Obesity-focused biotech raises $60M to launch first human trial · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Vedanta gets $60M to finish Phase 3 for C. diff microbiome therapy.” Browse more stories.